Article PDF
Avoid common mistakes on your manuscript.
References
Alvandi, F., Kwitkowski, V.E., Ko, C.W., Rothmann, M.D., Ricci, S., Saber, H., Ghosh, D., Brown, J., Pfeiler, E., Chikhale, E., et al. (2014). U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia. Oncologist 19, 94–99.
Bai, C., Zhong, Q., and Gao, G.F. (2022). Overview of SARS-CoV-2 genome-encoded proteins. Sci China Life Sci 65, 280–294.
Consortium, W.S.T. (2021). Repurposed antiviral drugs for COVID-19—interim WHO solidarity trial results. N Engl J Med 384, 497–511.
Garreau de Loubresse, N., Prokhorova, I., Holtkamp, W., Rodnina, M.V., Yusupova, G., and Yusupov, M. (2014). Structural basis for the inhibition of the eukaryotic ribosome. Nature 513, 517–522.
Hammond, J., Leister-Tebbe, H., Gardner, A., Abreu, P., Bao, W., Wisemandle, W., Baniecki, M.L., Hendrick, V.M., Damle, B., Simón-Campos, A., et al. (2022). Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med doi: https://doi.org/10.1056/NEJMoa2118542.
Jayk Bernal, A., Gomes da Silva, M.M., Musungaie, D.B., Kovalchuk, E., Gonzalez, A., Delos Reyes, V., Martín-Quirós, A., Caraco, Y., Williams-Diaz, A., Brown, M.L., et al. (2022). Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. N Engl J Med 386, 509–520.
McCallum, M., Czudnochowski, N., Rosen, L.E., Zepeda, S.K., Bowen, J. E., Walls, A.C., Hauser, K., Joshi, A., Stewart, C., Dillen, J.R., et al. (2022). Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. Science 375, 864–868.
Perlman, S., and McIntosh, K. (2020). Coronaviruses, including severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). In: Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 9th ed. Philadelphia: Elsevier.
Ruan, Y., Hou, M., Tang, X., He, X., Lu, X., Lu, J., Wu, C.I., and Wen, H. (2022a). The runaway evolution of SARS-CoV-2 leading to the highly evolved Delta strain. Mol Biol Evol 39, msac046.
Ruan, Y., Wen, H., Hou, M., He Z., Lu X., Xue Y., He X., Zhang, Y.P., and Wu, C.I. (2022b). The twin-beginnings of COVID-19 in Asia and Europe—one prevails quickly. Natl Sci Rev 9, nwab223.
Schneider-Poetsch, T., and Yoshida, M. (2018). Along the central dogma—controlling gene expression with small molecules. Annu Rev Biochem 87, 391–420.
Simonis, A., Theobald, S.J., Fätkenheuer, G., Rybniker, J., and Malin, J.J. (2021). A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2. EMBO Mol Med 13, e13105.
Wen, H.J., Liu, F.L., Huang, M.X., Luo, R.H., He, W.B., Feng, J., Chen, F. L., Cai, Q.C., Ma, H.J., Yang, Z.F., et al. (2021). A proposal for clinical trials of COVID-19 treatment using homo-harringtonine. Natl Sci Rev 8, nwaa257.
Wu, C.I., and Wen, H. (2020). Heightened protein-translation activities in mammalian cells and the disease/treatment implications. Natl Sci Rev 7, 1851–1855.
Wu, C.I., Wen, H., Lu, J., Su, X.D., Hughes, A.C., Zhai, W., Chen, C., Chen, H., Li, M., Song, S., et al. (2021). On the origin of SARS-CoV-2—The blind watchmaker argument. Sci China Life Sci 64, 1560–1563.
Acknowledgements
This work was supported by the National Natural Science Foundation of China (81802939, 32150006, 31730046, and 81972691), the National Key Research and Development Projects of the Ministry of Science and Technology of China (2021YFC2301300), the National Key Research and Development Program of China (2021YFC0863400), Guangdong Basic and Applied Basic Research Foundation (2020B1515020030), the National Key Research and Development Project (2020YFC0847000), and the Innovation Group Project of Southern Marine Science and Engineering Guangdong Laboratory (Zhuhai; No. 311021006).
Author information
Authors and Affiliations
Corresponding authors
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Ma, H., Wen, H., Qin, Y. et al. Homo-harringtonine, highly effective against coronaviruses, is safe in treating COVID-19 by nebulization. Sci. China Life Sci. 65, 1263–1266 (2022). https://doi.org/10.1007/s11427-021-2093-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-021-2093-2